TrialSpark

Formation Bio, formerly named TrialSpark, is a technology-driven pharmaceutical company headquartered in New York, NY. Rather than focusing on drug discovery, it acquires or in-licenses clinical-stage assets from pharmaceutical companies, biotechs and universities and develops them through a proprietary, AI-native drug development platform intended to reach clinical inflection points faster and at lower cost than industry norms. The company describes deal structures as flexible, spanning acquisition, in-licensing, co-development, joint ventures and NewCos, and has also used capital to invest in biotech companies holding drug candidates ready for development.

The original TrialSpark product was a software platform that integrated the front end of clinical trials (patient recruitment, eConsent, eSource) with the back end (data management, monitoring and biostatistics) to eliminate siloed study data. The company has acted across the clinical trial value chain in roles including recruitment vendor, technology partner, trial site manager and CRO, and by 2024-2025 had supported hundreds of studies. Its stated positioning contrasts with the traditional model in which sponsors outsource trials to contract research organizations on a cost-plus, billable-hour basis, which company leadership argues incentivizes longer and costlier trials.

As of the sources, the team and advisors had been involved in over 75 regulatory submissions (as of May 2024) and more than 45 approved drugs (as of April 2025). The company frames its market thesis around a widening gap between accelerating drug discovery output and the rising cost of clinical development, citing full drug development costs of roughly $800 million to $2.3 billion as of 2024 and Phase 3 programs costing over $100 million as of 2025.

Founding story

Public sources report that the company was founded as TrialSpark in 2016 by Benjamine (Ben) Liu, who became CEO, together with Linhao Zhang and Kit Dobyns (Contrary Research dates the founding to June 2013 in its profile header while describing a 2016 founding in the narrative; internal records date founding to 2013). Liu, an immigrant from Taiwan, earned a B.S. in biology from Yale, an M.Phil. in computational biology from the University of Cambridge as a Paul Mellon Scholar, and a D.Phil. at the University of Oxford as a Rhodes Scholar. During his graduate research he identified candidate drugs, including for Parkinson's disease, and found that pharmaceutical companies declined to advance them because they lacked bandwidth and resources for additional trials rather than for scientific reasons; he concluded the bottleneck in drug development had moved from discovery to clinical execution. He co-founded the company while still completing his doctorate. Zhang, a computer science graduate of the University of Texas at Austin and a former engineer at Salesforce and Oscar Health, served as CTO and later as COO. Dobyns studied at Cornell University and was also a Rhodes Scholar at Oxford; he and Liu were assigned as roommates during Rhodes pre-orientation, while Dobyns and Zhang had met as roommates during a Salesforce internship.

Business model

The company acquires or in-licenses clinical-stage drug assets from pharmaceutical companies, biotechs and universities and develops them in-house using its own trial platform, aiming to capture greater value per program by reaching development inflection points earlier. Deal structures cited include acquisition, in-licensing, co-development, joint ventures and NewCos, plus investment in biotech companies with drug candidates ready for development. Historically it also provided services across the trial lifecycle as a recruitment vendor, technology partner, site manager and CRO.

Sources do not state a definitive revenue model; the company positions itself as an asset owner/developer of in-licensed clinical-stage drugs rather than a cost-plus, billable-hour contract research organization. Growjo lists an estimated (not company-reported) annual revenue of $36 million.

Traction

Supported hundreds of studies across the clinical trial timeline in roles ranging from recruitment vendor and tech partner to site manager and CRO (as of 2024-2025). Team and advisors involved in over 75 regulatory submissions as of May 2024 and over 45 approved drugs as of April 2025. Company materials from the 2021 Series C claimed 50% faster study timelines and 95% of patients unlocked who were previously unreached by clinical trials. Employee counts reported range from 110 (Forbes, August 2022) to 193 (Contrary Research) and 232 (Growjo estimate).

Latest developments

Mike Ehlers joined as Chief Scientific Officer and Head of R&D (announced on the company website). The company now operates under the Formation Bio name and describes itself as an AI-native pharma company acquiring and developing clinical-stage assets through flexible structures and financing pathways. Contrary Research's profile, updated January 22, 2026, lists the company as private at Series D stage with total funding of $528 million and 193 employees.